Geron Corp (GERN) Stock Price, Quote & News

Company Profile

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractor...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 473 7700

Website: www.geron.com

Address:

919 East Hillsdale Boulevard, Suite 250, Foster City, United States

Twillery Apr. 30 at 5:57 AM

$GERN From Perplexity on the IMpactMF study: "Public documents do not disclose the exact O’Brien‑Fleming or alpha‑spending parameters, so the numerical probability of an early stop in 2026 cannot be calculated precisely. However, if: The Phase II IMbark signal (e.g., ~29.9 months median OS vs ~14–16 months in historical controls) translates cleanly into IMpactMF, Crossover is limited or happens late, and The trial’s statistical plan allocates a non‑trivial fraction of alpha to the interim look, then the subjective probability of an early stop for efficacy in 2026 would be in the “moderate but not high” range: perhaps in the ballpark of 20–40%, in the sense of a well‑informed investor view, not a formal statistical calculation."

0 · Reply

BubblesMcGee123 Apr. 30 at 3:41 AM

$GERN I read the following: "Hedge funds and institutional investors in total hold approximately 478.8 million shares, representing a significant majority of the company's ownership." But what does that exactly mean? If I understand it, all it means is that RA Capital, for example, would lose some money, not much, but its investors, which include pension funds and insurance companies, would lose the real money. RA Capital may lose some reputational value, but that's easily recouped with their next big win, which they'll undoubtedly have. Is it possible that Geron's big institutional investors don't care all that much whether Geron wins or fails.

1 · Reply

ZoeyTanner Apr. 29 at 6:47 PM

$GERN Small caps and biotech are beaten to a pulp. What else is new. Five business days will reveal just what the hell Harout and team has been up to? It is all about the sales and MF. Eu is not even in the conversations. At ONE f dollar fifty, beggars cannot be choosey. Tuts can outlast anyone especially small fry retail. Time matters to no one, except retail who hold.

1 · Reply

BubblesMcGee123 Apr. 29 at 4:45 PM

$GERN I don't understand the discussion between biopearl and thirdarm on Imetelchat. Both extremely smart people and both with a much greater and intricate understanding of Geron's science than mine; however, the one point I think they're missing, unless I'm missing their points, is the all or none regarding the IMpactMF trial, stopping for efficacy in 2026, and a buyout. In fact, if the IDMC demands a continuation to 2028 that's excellent news for a 2027 buyout, not dead money until a 2029 FDA approval, as one of them wrote.

1 · Reply

share97 Apr. 29 at 4:43 PM

$GERN dead untill we see a survival benefit in MF

1 · Reply

ZaraSeagrove Apr. 29 at 12:22 AM

$GERN If Geron moved imetelstat-Rytelo into an injectable, which will make it just as easy to take as Reblozyl, it should replace Reblozyl as first-line treatment because it's a far superior drug. It will also become considerally cheaper to use than it is now, as an infusion. From AI: "The Progress: Moving to a subcutaneous (SQ) version is the most logical next step. It would put Rytelo on equal footing with Reblozyl’s "easy-in, easy-out" clinic visits. Engineers are working on high-concentration formulations that would allow for a small, subcutaneous "jab" rather than a long drip ... If Geron delivers a subcutaneous [injectable] Rytelo, the "first-line" label might just become a formality. The combination of disease modification (reducing the malignant clones) and convenience would make it very hard for doctors to justify starting with anything else."

1 · Reply

ZaraSeagrove Apr. 28 at 11:50 PM

$GERN Is it possible that imetelstat-Rytelo will replace Reblozyl as a first-line treatment, specifically for MDS, particularly when the overblown issue of cytopenias is resolved and as hematologists become more comfortable and better-trained regarding imetelstat-Rytelo. I suppose the FDA would demand another trial in order for imetelstat to become the first-line MDS treatment, but maybe not if the drug proves itself in other ways and becomes an oft-used off-label drug. I'm not sure how that protocol works.

0 · Reply

afc2881 Apr. 28 at 9:06 PM

$GERN Big news from Makary today about the future of clinical trials. https://x.com/i/status/2049198445454315759

0 · Reply

SaTwits Apr. 28 at 8:56 PM

$GERN tightening

0 · Reply

Huntlardo Apr. 28 at 7:23 PM

$GERN MACD on the monthly chart getting ready to cross up for the first time sense early 2024…

0 · Reply

Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026

Apr 20, 2026, 4:05 PM EDT - 10 days ago

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 14, 2026, 4:05 PM EDT - 16 days ago

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 13, 2026, 11:00 AM EDT - 17 days ago

Geron Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 13, 2026, 8:00 AM EDT - 17 days ago

Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary

Apr 6, 2026, 8:00 AM EDT - 24 days ago

Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference

Mar 26, 2026, 8:00 AM EDT - 5 weeks ago

Geron Announces Appointment of New Members to its Board of Directors

Mar 10, 2026, 10:30 AM EDT - 7 weeks ago

Geron Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 2, 2026, 1:10 PM EST - 2 months ago

Geron Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 8:00 AM EST - 2 months ago

Geron Earnings Call Transcript: Q4 2025

Feb 25, 2026, 7:00 AM EST - 2 months ago

Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Feb 23, 2026, 8:00 AM EST - 2 months ago

Geron Plans to Present at Upcoming Investor Conferences

Feb 18, 2026, 9:04 AM EST - 2 months ago

Top 3 Health Care Stocks That May Collapse This Quarter

AZN MASI

Feb 11, 2026, 7:27 AM EST - 2 months ago

Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

Jan 12, 2026, 8:00 AM EST - 3 months ago

Geron Corporation Provides 2026 Financial Guidance

Dec 11, 2025, 8:00 AM EST - 5 months ago

Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation

Dec 8, 2025, 8:02 AM EST - 5 months ago

Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

Dec 2, 2025, 11:15 AM EST - 5 months ago

Geron Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 11, 2025, 10:40 AM EST - 6 months ago

Geron Transcript: Stifel 2025 Healthcare Conference

Nov 5, 2025, 8:00 AM EST - 6 months ago

Geron Earnings Call Transcript: Q3 2025

Nov 5, 2025, 7:00 AM EST - 6 months ago

Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 4, 2025, 8:00 AM EST - 6 months ago

Geron Corporation to Present at Upcoming Investor Conferences

Nov 3, 2025, 9:05 AM EST - 6 months ago

Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies

Oct 27, 2025, 8:00 AM EDT - 6 months ago

Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025

Oct 13, 2025, 4:34 PM EDT - 7 months ago

Geron Corporation Announces Executive Leadership Transitions and Appointments

Aug 27, 2025, 4:05 PM EDT - 8 months ago

Geron to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 14, 2025, 5:23 PM EDT - 9 months ago

Geron Corporation Investors: Company Investigated by the Portnoy Law Firm

Aug 6, 2025, 8:00 AM EDT - 9 months ago

Geron Earnings Call Transcript: Q2 2025

Aug 6, 2025, 7:01 AM EDT - 9 months ago

Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 6, 2025, 7:00 AM EDT - 9 months ago

Geron Appoints Harout Semerjian as President and Chief Executive Officer

Jul 28, 2025, 8:00 AM EDT - 9 months ago

Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025

May 28, 2025, 8:30 AM EDT - 1 year ago

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

May 8, 2025, 11:24 PM EDT - 1 year ago

GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm

May 7, 2025, 12:33 PM EDT - 1 year ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN

May 7, 2025, 8:00 AM EDT - 1 year ago

Geron Earnings Call Transcript: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 24, 2025, 9:33 PM EDT - 1 year ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Apr 18, 2025, 4:30 PM EDT - 1 year ago

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 9, 2025, 10:40 AM EDT - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

Mar 3, 2025, 3:10 PM EST - 1 year ago

Geron Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 8:00 AM EST - 1 year ago

Geron Earnings Call Transcript: Q4 2024

Dec 4, 2024, 8:20 AM EST - 1 year ago

Geron Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 18, 2024, 1:50 PM EST - 1 year ago

Geron Transcript: Stifel 2024 Healthcare Conference

Nov 7, 2024, 8:00 AM EST - 1 year ago

Geron Earnings Call Transcript: Q3 2024

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Geron Earnings Call Transcript: Q2 2024

Jun 7, 2024, 8:00 AM EDT - 2 years ago

Geron Transcript: FDA Announcement

May 2, 2024, 8:00 AM EDT - 2 years ago

Geron Earnings Call Transcript: Q1 2024

Apr 17, 2024, 11:30 AM EDT - 2 years ago

Geron Transcript: Stifel Virtual Targeted Oncology Days Conference

Apr 10, 2024, 10:15 AM EDT - 2 years ago

Geron Transcript: 23rd Annual Needham Virtual Healthcare Conference

Feb 28, 2024, 8:00 AM EST - 2 years ago

Geron Earnings Call Transcript: Q4 2023

Nov 29, 2023, 10:50 AM EST - 2 years ago

Geron Transcript: 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 9:30 AM EST - 2 years ago

Geron Transcript: The Piper Sandler 35th Annual Healthcare Conference

Nov 2, 2023, 9:00 AM EDT - 2 years ago

Geron Earnings Call Transcript: Q3 2023

Sep 12, 2023, 4:55 PM EDT - 2 years ago

Geron Transcript: Baird's Global Healthcare Conference 2023

Aug 3, 2023, 4:30 PM EDT - 2 years ago

Geron Earnings Call Transcript: Q2 2023

May 11, 2023, 10:30 AM EDT - 3 years ago

Geron Earnings Call Transcript: Q1 2023

Mar 16, 2023, 4:30 PM EDT - 3 years ago

Geron Earnings Call Transcript: Q4 2022

Jan 4, 2023, 11:00 AM EST - 3 years ago

Geron Transcript: Study Result

Nov 3, 2022, 6:00 AM EDT - 3 years ago

Geron Earnings Call Transcript: Q3 2022

Aug 11, 2022, 9:00 AM EDT - 4 years ago

Geron Earnings Call Transcript: Q2 2022

May 9, 2022, 5:31 AM EDT - 4 years ago

Geron Earnings Call Transcript: Q1 2022

Mar 10, 2022, 5:43 AM EST - 4 years ago

Geron Earnings Call Transcript: Q4 2021

Nov 9, 2021, 4:00 PM EST - 4 years ago

Geron Transcript: Investor Update

Nov 9, 2021, 10:21 AM EST - 4 years ago

Geron Earnings Call Transcript: Q3 2021

Aug 15, 2021, 8:00 PM EDT - 5 years ago

Geron Earnings Call Transcript: Q2 2021

May 10, 2021, 4:30 PM EDT - 5 years ago

Geron Earnings Call Transcript: Q1 2021

Mar 11, 2021, 4:30 PM EST - 5 years ago

Geron Earnings Call Transcript: Q4 2020

Nov 5, 2020, 4:30 PM EST - 5 years ago

Geron Earnings Call Transcript: Q3 2020

Aug 6, 2020, 4:30 PM EDT - 6 years ago

Geron Earnings Call Transcript: Q2 2020

Jun 17, 2020, 8:00 AM EDT - 6 years ago

Geron Transcript: KOL Event

May 28, 2020, 4:30 PM EDT - 6 years ago

Geron Earnings Call Transcript: Q1 2020

Twillery Apr. 30 at 5:57 AM

0 · Reply

BubblesMcGee123 Apr. 30 at 3:41 AM

1 · Reply

ZoeyTanner Apr. 29 at 6:47 PM

1 · Reply

BubblesMcGee123 Apr. 29 at 4:45 PM

1 · Reply

share97 Apr. 29 at 4:43 PM

$GERN dead untill we see a survival benefit in MF

1 · Reply

ZaraSeagrove Apr. 29 at 12:22 AM

1 · Reply

ZaraSeagrove Apr. 28 at 11:50 PM

0 · Reply

afc2881 Apr. 28 at 9:06 PM

$GERN Big news from Makary today about the future of clinical trials. https://x.com/i/status/2049198445454315759

0 · Reply

SaTwits Apr. 28 at 8:56 PM

$GERN tightening

0 · Reply

Huntlardo Apr. 28 at 7:23 PM

$GERN MACD on the monthly chart getting ready to cross up for the first time sense early 2024…

0 · Reply

BubblesMcGee123 Apr. 28 at 2:54 AM

$GERN I don't understand these price targets, listed on TipRanks, which are essentially based on Geron's LR-MDS sales -- I don't think these targets are factoring in the ImpactMF, AML, and HR-MDS trials. Why are Wedbush and Needham predicting $4 and $5, whereas Goldman Sachs has a $1 target? Wasn't Goldman Sachs a lead underwriter for Geron, even as late as 2023? What's going on there? Plus, Goldman Sachs is currently one of Geron's top institutional investors.

2 · Reply

tc719 Apr. 27 at 6:22 PM

$GERN biopearl goes esoteric .... boa

0 · Reply

GISBlaster98 Apr. 27 at 11:39 AM

$GERN Lilly to buy Ajax Therapeutics $2.3B

0 · Reply

Huntlardo Apr. 26 at 9:54 AM

$GERN New Clinical Trial listed: NCT07549451. Why it matters This kind of listing usually signals that Geron is broadening imetelstat’s development program into another hematologic disease area. For investors, the key question is whether the trial can show enough activity in MDS/MPN to justify later-stage development. NCT07549451 looks like an expansion study into a new blood-cancer setting, so it is earlier and more exploratory.

2 · Reply

BubblesMcGee123 Apr. 25 at 7:58 AM

$GERN I'm looking forward to Geron's imetelstat becoming a platform drug, so that it will be used in many drug combinations and for many blood cancers, moving beyond LR-MDS, HR-MDS, AML, MF to multiple myeloma, different types of lymphomas, leukemias, and neoplasms.

0 · Reply

GangsterX Apr. 24 at 8:47 PM

$PMVP $GERN $REPL still holding.. 3 biggies

0 · Reply

ZoeyTanner Apr. 24 at 4:41 AM

$GERN Never ending hanging retail out to dry. MMs, tuts, leadership, short funds, swing traders all there to fill investors with chaos. Will there ever be a day of joy for those holding?

0 · Reply

Twillery Apr. 24 at 2:38 AM

$GERN From AI, just a mathematical perspective: The IMpactMF trial is a binary event, and "The 'Bet': Watch the hazard ratio (HR). If the interim data in late 2026 shows a hazard ratio below 0.70 (meaning a 30% reduction in the risk of death), the trial is in excellent shape for a final win." AI is saying, if the IDMC does not stop the trial for efficacy in 2026, we would hope the above numbers reflect the interim results.

1 · Reply

meistermell Apr. 22 at 5:38 PM

$GERN

0 · Reply

Twillery Apr. 22 at 5:21 PM

$GERN I wonder when the results from the phase 2 trials of AML and HR-MDS will be announced. Supposedly sometime in the second half of 2026, so perhaps we'll hear at the EHA in June or ASH in December.

0 · Reply

vonryan Apr. 22 at 3:43 PM

$GERN We need to hear some awesome earnings and growth news.

0 · Reply

patso1964 Apr. 22 at 2:34 PM

$GERN https://ir.geron.com/news-releases/news-release-details/geron-plans-announce-first-quarter-2026-financial-results-may-6

0 · Reply

Market Cap	967.76M
Revenue (ttm)	183.88M
Net Income (ttm)	-83.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-45.41%
Debt to Equity Ratio	0.53

Volume	11,151,259
Avg Vol	19,384,689
Day's Range	N/A - N/A
Shares Out	640.90M
Stochastic %K	15%
Beta	0.67
Analysts	Sell
Price Target	$3.40